Stockscreener 앱 받기
0.1114
37.27%
-0.0662
시장 영업 전:
.11
-0.0014
-1.26%
전일 마감가:
$0.1776
열려 있는:
$0.1479
하루 거래량:
44.56M
Relative Volume:
4.53
시가총액:
$46.15M
수익:
$39.55M
순이익/손실:
$-122.93M
주가수익비율:
-0.2519
EPS:
-0.4423
순현금흐름:
$-97.31M
1주 성능:
-44.58%
1개월 성능:
-62.88%
6개월 성능:
-79.75%
1년 성능:
-84.53%
1일 변동 폭
$0.1051
$0.1999
1주일 범위
$0.1051
$0.217
52주 변동 폭
$0.1051
$0.766
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Compare SGMO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.1114 | 73.58M | 39.55M | -122.93M | -97.31M | -0.4423 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-12-13 | 업그레이드 | Truist | Hold → Buy |
| 2024-12-10 | 재확인 | H.C. Wainwright | Buy |
| 2023-11-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-04-28 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-02-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2021-05-04 | 개시 | RBC Capital Mkts | Outperform |
| 2021-01-07 | 재개 | Guggenheim | Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-12-16 | 재개 | H.C. Wainwright | Buy |
| 2020-09-08 | 개시 | BofA Securities | Buy |
| 2020-07-07 | 개시 | SunTrust | Buy |
| 2019-08-26 | 개시 | H.C. Wainwright | Buy |
| 2018-11-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2018-10-10 | 개시 | Guggenheim | Buy |
| 2018-06-20 | 개시 | BofA/Merrill | Buy |
| 2017-11-15 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | 재개 | Jefferies | Buy |
| 2016-11-01 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2016-10-19 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-10-23 | 재개 | Jefferies | Buy |
| 2013-05-03 | 개시 | BioLogic Equity Research | Sell |
| 2011-02-23 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-07-29 | 재확인 | Wedbush | Outperform |
| 2009-10-19 | 개시 | Brean Murray | Sell |
| 2009-10-07 | 재확인 | Leerink Swann | Outperform |
| 2009-08-25 | 재확인 | JMP Securities | Mkt Outperform |
모두보기
Sangamo Therapeutics Inc 주식(SGMO)의 최신 뉴스
Price to earnings ratio of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Total revenue of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Sangamo Therapeutics, Inc. Cash Flow – OTC:SGMO - TradingView
Enterprise value to EBITDA ratio of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Net debt of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Cost of goods sold of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Sangamo Therapeutics, Inc. Balance Sheet – OTC:SGMO - TradingView
Operating income of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Sangamo Therapeutics, Inc. Revenue Breakdown – OTC:SGMO - TradingView
Net current asset value per share of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Long term debt to total equity ratio of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
EBIT per share of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
EBITDA margin % of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Sangamo Therapeutics, Inc. Income Statement – OTC:SGMO - TradingView
Sangamo Therapeutics, Inc. Earnings and Revenue – OTC:SGMO - TradingView
Sangamo Stock Jumps Before Nasdaq Exit: Why SGMO Investors Are Watching May 5 - TechStock²
Sangamo Therapeutics (SGMO) to Release Earnings on Monday - MarketBeat
Sangamo Therapeutics | 10-K/A: Annual report (Amendment) - Moomoo
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Update - MarketBeat
SGMO Forecast, Price Target & Analyst Ratings | SANGAMO THERAPEUTICS INC (NASDAQ:SGMO) - ChartMill
MSN Money - MSN
Sangamo Therapeutics 2025 Executive Compensation, Stock Awards, and Corporate Objectives Overview - Minichart
Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) - The Manila Times
SGMO Financials: Income Statement, Balance Sheet & Cash Flow | Sangamo Therapeutics Inc - Stock Titan
H.C. Wainwright Reaffirms Their Buy Rating on Sangamo Therapeutics (SGMO) - The Globe and Mail
SANGAMO THERAPEUTICS, INC. (SGMO) - MSN
Sangamo stock leaves Nasdaq May 5 but keeps SGMO ticker on OTCQB - Stock Titan
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Sangamo Therapeutics to be delisted from Nasdaq, trading to move to OTCQB - Investing.com Nigeria
Sangamo Therapeutics (SGMO) Nasdaq delisting shifts stock to OTCQB market - Yahoo Finance
Sangamo Therapeutics, Inc. Files Form 8-K with SEC – Key Company and Stock Information (April 2026) - Minichart
Sangamo Therapeutics | 8-K: Current report - Moomoo
Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market - The Manila Times
Sangamo Therapeutics To Transition Common Stock To Otcqb Venture Market On May 5, 2026 - TradingView
Crude Oil Jumps 5%; Automatic Data Processing Posts Upbeat Earnings - Sahm
Q2 2025 Sangamo Therapeutics Inc Earnings Call Transcript - GuruFocus
Q1 2025 Sangamo Therapeutics Inc Earnings Call Transcript - GuruFocus
Q3 2025 Sangamo Therapeutics Inc Earnings Call Transcript - GuruFocus
Gregory Davis Sells 69,827 Shares of Sangamo Therapeutics (NASDAQ:SGMO) Stock - MarketBeat
Sangamo Therapeutics (NASDAQ:SGMO) SVP Sells $89,944.92 in Stock - MarketBeat
Sangamo Therapeutics SVP sells $89,183 in common stock - Investing.com
Sangamo Therapeutics’ head of research & technology sells $17,694 in stock - Investing.com
Sangamo Therapeutics (SGMO) Stock Fundamentals | Sangamo Therapeutics Inc. misses EPS ests by 79.7%Stock Trading Network - UBND thành phố Hải Phòng
Sangamo targets summer 2026 for Fabry BLA submission while advancing neurology pipeline and partner talks - MSN
Sangamo Therapeutics prices $23M securities offering - MSN
SGMO ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Sangamo Therapeutics, Inc. Shareholders Who Lost Money - ACCESS Newswire
Sangamo Therapeutics (NASDAQ:SGMO) Lowered to Strong Sell Rating by Zacks Research - MarketBeat
SGMO News | SANGAMO THERAPEUTICS INC (NASDAQ:SGMO) - ChartMill
Fabry Disease Market Set for Robust Growth by 2034, Driven by Gene Therapy Breakthroughs and Expanding Pipeline from Sangamo, Sanofi, Amicus & Emerging Innovators | DelveInsight - Barchart.com
HC Wainwright Has Negative Forecast for SGMO FY2026 Earnings - MarketBeat
Analyst Calls: Will Sangamo Therapeutics Inc benefit from geopolitical trendsPortfolio Risk Summary & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Sangamo Therapeutics Inc (SGMO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):